At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 219 enrolled
Drug / intervention
Apremilast 30 mg +1 moredrug
Likely dose
Apremilast 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Apremilast 30 mg and Placebo for Psoriatic Arthritis. Completed, enrolled 219 participants across 71 sites in 10 countries.
Detailed Summary
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesAustralia, Canada, Czechia, Estonia, Hungary, New Zealand, Romania, Russia, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartSep 2013
Primary CompletionFeb 2015
Study CompletionNov 2016
TodayJul 2026
First PostedAug 20, 2013
Enrollment StartSep 4, 2013
Primary CompletionFeb 25, 2015
Study CompletionNov 17, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.9 years ago
Interventions
Apremilast 30 mgdrug
30mg of Apremilast will be orally administered twice daily for 104 weeks
Placebodrug
Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks